The heparin‑induced thrombocytopenia (HIT) treatment market is growing due to increasing adoption of non‑heparin anticoagulants (e.g., direct thrombin inhibitors), enhanced HIT scoring systems, and rapid diagnostic testing protocols in hospital settings. https://www.datamintelligence.com/research-report/heparin-induced-thrombocytopenia-market